# Paradigm Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paradigm-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Cambridge, UK
- Website: www.takedacam.com
- Total disclosed funding: $32M
- Latest round: Series D (Jul 7, 2006)
- Investors on record: 7

## About

Paradigm Therapeutics Ltd is a biotechnology company focused on developing innovative therapeutics. They specialize in addressing critical healthcare needs through advanced drug discovery and development processes.Paradigm Therapeutics Ltd, founded in 1998 and headquartered in Cambridge, UK, operates in the biopharmaceutical sector. The company has undergone strategic pivots to refine its focus on novel therapeutics. Robert Ryan serves as the CEO, guiding the company's operations. In March 2007, Takeda Pharmaceutical Company Limited acquired Paradigm Therapeutics Ltd after an investment round that raised GBP 7.000 mn, with participation from investors including Avlar BioVentures and LDC. The firm has executed a total of 4 deals to date.Paradigm Therapeutics specializes in the research and development of therapeutic solutions aimed at unmet medical needs. Their product offerings include innovative drug candidates designed to address various diseases by leveraging advanced biopharmaceutical technologies. Primarily targeting the healthcare sector, Paradigm is engaged in developing compounds that enhance treatment efficacy and patient outcomes.In the most recent fiscal year 2023, Paradigm Therapeutics reported a revenue of GBP 2,104,041.10 with an EBITDA of GBP 1,198,519.70, reflecting their operational focus and strategic product development.Moving forward, Paradigm Therapeutics plans to expand its product portfolio with upcoming therapeutic candidates designed to treat challenging medical conditions. The company is also looking to penetrate new geographic markets, particularly in North America and parts of Asia, by 2025. Funding raised from the recent Series D round will be allocated to accelerate research and development initiatives and support market entry strategies.

## Funding rounds

- Series D, Jul 7, 2006, $13M — Avlar BioVentures, LDC, SG Growth Capital, Merlin Biosciences Fund Ltd
- Series B, Dec 9, 2002, $19M — Avlar BioVentures, Biomedical Sciences Investment Fund, Genmab A/S, Technomark Medical Ventures

## Investors

- Avlar BioVentures (https://capitalatlas.ai/funds/avlar-bioventures) — Series B, Series D
- Biomedical Sciences Investment Fund — Series B
- Genmab A/S — Series B
- Technomark Medical Ventures — Series B
- LDC (https://capitalatlas.ai/funds/ldc) — Series D
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series D
- Merlin Biosciences Fund Ltd — Series D